- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.01. | Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating | 1 | Investing.com | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.01. | Bicara Therapeutics: Citizens startet Coverage mit "Market Outperform" und hohem Kursziel | 2 | Investing.com Deutsch | ||
| 15.01. | Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress | 1 | Investing.com | ||
| 12.01. | Bicara legt optimale Dosis für zulassungsrelevante Studie zu Kopf-Hals-Krebs fest | 1 | Investing.com Deutsch | ||
| 12.01. | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | BTIG nimmt Coverage für Bicara Therapeutics mit "Buy"-Rating auf | 2 | Investing.com Deutsch | ||
| 08.01. | BTIG initiates coverage on Bicara Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 17.12.25 | Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating | 1 | Investing.com | ||
| 17.12.25 | Mizuho startet Coverage für Bicara Therapeutics mit "Neutral"-Einstufung | - | Investing.com Deutsch | ||
| 08.12.25 | Bicara stock maintains Buy rating at Stifel after ESMO-Asia data | 2 | Investing.com | ||
| 08.12.25 | Bicara: Stifel bestätigt Kaufempfehlung nach ESMO-Asia-Daten | 1 | Investing.com Deutsch | ||
| 08.12.25 | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.12.25 | Bicara Therapeutics Inc.: Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 | 138 | GlobeNewswire (Europe) | Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study... ► Artikel lesen | |
| 01.12.25 | Bicara: Krebswirkstoff Ficerafusp Alfa zeigt auch bei niedrigerer Dosis konstante Ansprechraten | 1 | Investing.com Deutsch | ||
| 01.12.25 | Bicara's ficerafusp alfa shows consistent response rates at lower dose | 1 | Investing.com | ||
| 10.11.25 | Bicara Therapeutics GAAP EPS of -$0.67 | 3 | Seeking Alpha | ||
| 10.11.25 | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 172 | GlobeNewswire (Europe) | Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp... ► Artikel lesen | |
| 10.11.25 | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.10.25 | Bicara stock jumps after FDA grants breakthrough therapy status | 2 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
BICARA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,250 (+1,66 %) liegt der Kurs bei 15,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.